Foundation Investigation Biomedical Hospital 12 de Octubre + CNIO
Lines of investigation:
Characterization molecular and immune Cancer from lung microcytic and no microcytic as a basis for customizing immunotherapy strategies
Sequencer Ion Torrent S5 XL, Sequencer Illumina NextSeq500, ultrasonicator COVARIS, core of immunohistochemistry (HRP, FISH), cytometers and sorters (core CNIO), Digital Droplet PCR (BioRad) with auto-droplet generator (robot automated), qPCR
Preparation from bookstores NGS (Illumina and Ion Torrent), disintegration from tumors cool to suspension cellular, separation from populations immune by FACS (sorting), marking by immunohistochemistry from tissue FFPE, marking and permeabilization from populations cell phones.
Protocols from culture and expansion of TILs, protocols of NGS in biopsy liquid, IHC Multiplex, Bioinformatics
CART therapy in clinical phase (CART19 in progress, CART-BCMA in preparation), CART therapy in pre-clinical phase (CD1a, CD123, HER2), TIL therapy in pre-clinical phase
Ongoing clinical trials with CART therapy. Production escalation protocols lentiviral(GMP). TIL protocols in preparation
Improvements in the CAR sequence. Humanization of scFvs. Development of "safety-switch"novel (not patented). Optimization of production protocols. Development of new control strategies for the release syndrome cytokines.
Redirect from T cells to tumors. Development and characterization of bispecific antibodies for the treatment of breast and colon cancer.
Models from mice humanized by PBMCs
Models from mice humanized from cells parents CD34+.
Co-cultures of PBMCs and organoids (to depart of PDXs of Cancer breast, pancreas, gastric or colorectals).
Cytometry from flow for determination from populations immune in blood and intra-tumorous.
Generation of humanized mice, both with PBMCs and CD34 + progenitor cells, in patient derived xenograft (PDX) models. In vitro co-culture assays of PBMCs and tumor cells. Analysis of immune populations in disintegrated tumors.
Institute Maimonides of Biomedical Research of Córdoba (IMIBIC)
Lines of investigation:
Cancer Colorectal - Establishment and development of humanized models of patient derived xenographs (PDX) for study of response to immunotherapy in combination with other targeted therapies. - Establishment and development of colonies and organoids of cancer colorectal - Characterization of the different molecular subtypes of cancer colorectal and relationship with the immune microenvironment and the antitumor response.
Biobank from PDXs of colorectal cancer classified molecularly.
Unit of Cytometry flow
Protocols from establishment of PDXs. - Protocols from isolation of PBMCs. - Protocols of humanization through PBMCs.
New approaches for the study of the tumor immune microenvironment and tumor response study in different preclinical models.
- Support in the development of specific protocols for other types of tumor, eg. breast and lung cancer.
- Collaborations in projects related to immune-oncology.
Salamanca Cancer Research Center (IBMCC, Centro Mixto Universidad de Salamanca - CSIC)
Lines of investigation:
Study area: Immunology and Cancer (both with regard to the relationship between the immune system and cancer, as well as the study of neoplasms / clonal expansions derived from cells of the immune system and to the monitoring of the immune response after antitumor immunotherapy) Specific lines: 1.- Identification of aberrant protein expression patterns in hematological tumors and their use as markers of residual disease and for the identification of targets (immune) therapeutic. 2.- Design, development, standardization and validation of “Next Generation Flow cytometry Data ”for sensitive, fast and specific analysis of data from flow cytometry, applied to analysis immunophenotypic of hematological neoplasms. 3.- Design, development, standardization and validation of cytometry flow multiparametric (> 12 colors) of the latest generation for the identification of multiple populations of the immune system of functional relevance, for its application in the monitoring of the immune response after treatments immunotherapy (for example after antitumor immunotherapy).
Post-immunotherapy immune response monitoring by multiparametric flow cytometry.
Monitoring of minimal residual disease through cytometry (in the case of hematological neoplasms).
- Personnel training predoctoral and junior postdoctoral in functional trials additional to those performed in our group (eg ELISPOT technique).
- Training in molecular methods (especially NGS) applied to very scarce samples cellularity (<100 cells and <500 cells).
- Possibility of access to cell lines transfected in order to test anti-CD19 conjugated with fluorochrome to identify CART-cells
Molecular characterization of tumors and search for biomarkers and prognostic and predictive molecular profiles of response in various clinical scenarios (breast cancer, melanoma, colon, bladder, anus) through the use of omics techniques (NGS, genomics, proteomics and metabolomics) and computational analysis.
From the Oncology translational lab, we can help in the processing and analysis of biological and clinical samples (cells, tissues, FFPE biopsies) using omics techniques: high-throughput (NGS, genomics, proteomics and metabolomics).
We have also established a computational analysis pipeline (probabilistic graphical models, classificatory algorithms, Flux balance analysis, preparation of predictors and differential expression analysis) with which we can provide a deeper molecular characterization of tumors and the interpretation of the data obtained from a systems biology perspective.
Search for collaborations. Animal models of tumor disease and access to patient cohort samples for conducting studies.